GlassScriptPhysician profile
Adel G Sandouk
NPI 1043315575
$4,013.13
in general payments reported to CMS, 2019-2025
24 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $55.58 · 2021: $245 · 2022: $454 · 2023: $620 · 2024: $873 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.60 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $571.59 | 2019-2025 | Trelegy Ellipta, Nucala |
| Philips North America LLC | $463.73 | 2019-2025 | Encore, (8874) Incourage, Respiratory |
| Baxter Healthcare | $417.20 | 2022-2025 | Hillrom - Metaneb System, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Amgen INC. | $339.35 | 2019-2024 | Otezla |
| Mylan Specialty L.P. | $302.41 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $281.63 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.82 | 2021-2025 | Ofev |
| Insmed, INC. | $249.68 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $217.95 | 2019-2024 | |
| Inspire Medical Systems, INC. | $149.09 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $133.24 | 2019-2025 | Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $98.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $90.00 | 2024 | |
| Verona Pharma, INC. | $78.66 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $75.08 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $64.89 | 2021-2024 | Tyvaso |
| Electromed, INC. | $43.99 | 2021-2025 | Smartvest |
| Viatris Specialty LLC | $30.51 | 2025 | Yupelri |
| Cumberland Pharmaceuticals, INC. | $29.78 | 2022-2023 | Vibativ |
| Lilly USA, LLC | $27.12 | 2025 | Zepbound |
| Astellas Pharma US INC | $20.62 | 2025 | Cresemba |
| Ani Pharmaceuticals, INC. | $17.63 | 2024 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $16.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.91 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Sandouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.